// App-Quantinova.ai

AB0560 (2021) : EFFECT OF DEUCRAVACITINIB ON THE PSORIATIC ARTHRITIS IMPACT OF DISEASE (PsAID) QUESTIONNAIRES 12 AND 9: ANALYSIS OF A PHASE 2 STUDY OF ACTIVE PSORIATIC ARTHRITIS

Researchers

Presenter

  • L. Gossec

Principal Investigators

  • L. C. Coates

  • A. Ogdie

  • P. J. Mease

  • T. Lehman

  • M. Nowak

  • L. Wei

  • J. Ye

  • J. Choi

  • J. Zhuo

Medical Centers

  • Sorbonne Université, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

  • Perelman School of Medicine at the University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, Philadelphia, United States of America

  • 2Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, Washington, United States of America

  • Bristol-Myers Squibb, former employee, Princeton, United States of America

  • Bristol Myers Squibb, Medical Immunology, Princeton, United States of America

Locations

  • France

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • L-Tyrosine

  • IL-12

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • II

Study Id's

  • NCT03881059

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved